Recently, a large prospective cohort study (n = 427) showed increased serum SP-D values in concert with anti-topoisomerases I antibody were detectable in SSc-ILD with 97% sensitivity and 69% specificity [138]. Here, SFTPD is linked to systemic sclerosis.